Fusion Antibodies (LON:FAB) Stock Falls 20% – Should You Sell?

Fusion Antibodies plc (LON:FAB)’s stock price was down 20% during trading on Tuesday. The stock traded as low as GBX 4 and last traded at GBX 4. 1,953,875 shares were traded during mid-day trading, an increase of 322% from the average daily volume of 462,495 shares. The stock had previously closed at GBX 5.

Fusion Antibodies Trading Down 20.0%

The company has a current ratio of 2.82, a quick ratio of 2.36 and a debt-to-equity ratio of 20.41. The company has a market cap of £5.01 million, a PE ratio of -4.00 and a beta of 1.24. The stock has a 50 day moving average price of GBX 9.23 and a 200 day moving average price of GBX 11.72.

Fusion Antibodies (LON:FAB) last posted its quarterly earnings data on Monday, September 14th. The company reported GBX (1.20) earnings per share (EPS) for the quarter. Fusion Antibodies had a negative return on equity of 97.87% and a negative net margin of 54.45%. Sell-side analysts predict that Fusion Antibodies plc will post -130.00 EPS for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.